Currently, there are 64.03M common shares owned by the public and among those 36.46M shares have been available to trade.
The company’s stock has a 5-day price change of -5.56% and -38.28% over the past three months. LRMR shares are trading -51.68% year to date (YTD), with the 12-month market performance down to -76.30% lower. It has a 12-month low price of $1.61 and touched a high of $11.20 over the same period. LRMR has an average intraday trading volume of 1.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.75%, -14.05%, and -61.60% respectively.
Institutional ownership of Larimar Therapeutics Inc (NASDAQ: LRMR) shares accounts for 57.92% of the company’s 64.03M shares outstanding.
It has a market capitalization of $119.73M and a beta (3y monthly) value of 0.78. The earnings-per-share (ttm) stands at -$1.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.22% over the week and 7.93% over the month.
Analysts forecast that Larimar Therapeutics Inc (LRMR) will achieve an EPS of -0.49 for the current quarter, -0.51 for the next quarter and -1.75 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.51 while analysts give the company a high EPS estimate of -0.51. Comparatively, EPS for the current quarter was -0.34 a year ago. Earnings per share for the fiscal year are expected to decrease by -45.99%, and -2.24% over the next financial year. EPS should shrink at an annualized rate of -7.85% over the next five years, compared to 50.78% over the past 5-year period.
Looking at the support for the LRMR, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on January 29, 2025, with the firm’s price target at $18. Oppenheimer coverage for the Larimar Therapeutics Inc (LRMR) stock in a research note released on October 16, 2024 offered a Outperform rating with a price target of $26. Wedbush was of a view on October 03, 2024 that the stock is Outperform, while H.C. Wainwright gave the stock Buy rating on October 02, 2024, issuing a price target of $15. Robert W. Baird on their part issued Outperform rating on September 04, 2024.
